A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Cited by
Items 101–200 of 660
Park, H. J., Kim, Y. J., Kim, D. H., Kim, J., Park, K. H., Park, J., & Lee, J. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.1.118 · Cited by 98
Zhou, Y., & Lauschke, V. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02385-x · Cited by 98
Severe cutaneous adverse reactions
Chung, W., Mockenhaupt, M., Blumenthal, K. G., Abe, R., Ueta, M., Oro, S., Phillips, E. J., & Chung, W. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00514-0 · Cited by 98
Self-citationGout. Novel therapies for treatment of gout and hyperuricemia
Terkeltaub, R. A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2738 · Cited by 98
“Johnson syndrome or toxic epidermal necrolysis) [43-45],”
Pharmacogenomics of adverse drug reactions: implementing personalized medicine
Wei, C.-Y., Michael Lee, M.-T., & Chen, Y.-T. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds341 · Cited by 87
“Abacavir HLA-B∗5701 HSS Western Australian 117 (57) Allopurinol HLA-B∗5801 SCAR Han Chinese 580 (58) SJS/TEN Japanese 41 (59) SJS/TEN European 80 (60) Aminopenicillin HLA-A2 DHS Italian 7 (61) HLA-DRW52 DHS Italian 9 (13) Amoxicillin-clavulanate HLA-A∗0201 DILI Caucasian 2.”
BackgroundSukasem, C., Jantararoungtong, T., Kuntawong, P., Puangpetch, A., Koomdee, N., Satapornpong, P., Supapsophon, P., Klaewsongkram, J., & Rerkpattanapipat, T. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00186 · Cited by 95
“Maculopapular eruption (MPE) is recognized as a mild form of hypersensitivity reaction (Lonjou et al., 2008; Karlin and Phillips, 2014; Sasidharanpillai et al., 2015).”
BackgroundPascart, T., Latourte, A., Flipo, R., Chalès, G., Baumann, L., Solal, A. C., Ea, H., Grichy, J., Letavernier, E., Lioté, F., et al. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.05.002 · Cited by 95
Chiu, M. L. S., Hu, M. S., Ng, M. H. L., Yeung, C. K., Chan, J. C.-Y., Chang, M. M., Cheng, S. H., Li, L., & Tomlinson, B. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10894.x · Cited by 94
Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions
Kongpan, T., Mahasirimongkol, S., Konyoung, P., Kanjanawart, S., Chumworathayi, P., Wichukchinda, N., Kidkeukarun, R., Preechakul, S., Khunarkornsiri, U., Bamrungram, W., et al. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000153 · Cited by 94
Diphoorn, J. C. D., Cazzaniga, S., Gamba, C., Schroeder, J. W., Citterio, A. M., Rivolta, A. L., Vighi, G. D., Naldi, L., & The REACT-Lombardia study group (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3937 · Cited by 93
Self-citationKloypan, C., Koomdee, N., Satapornpong, P., Tempark, T., Biswas, M., & Sukasem, C. (2021) · Pharmaceuticals · doi:10.3390/ph14111077 · Cited by 92
Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA
Yun, J. J., Adam, J., Yerly, D., & Pichler, W. J. (2012) · Allergy · doi:10.1111/all.12008 · Cited by 91
“A number of studies have been conducted across various ethnic groups, and some of these have concluded that drug hypersensitivity and HLA association are dependent on ethnicity (22, 23).”
BackgroundRamírez, E., Bellón, T., Tong, H. Y., Borobia, A. M., de Abajo, F. J., Lerma, V., Moreno‐Hidalgo, M. Á., Castañer, J. L., Cabañas, R., Fiandor, A. M., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.027 · Cited by 89
HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis
Grover, S., & Kukreti, R. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000021 · Cited by 89
The genetics of gout: towards personalised medicine?
Dalbeth, N., Stamp, L. K., & Merriman, T. R. (2017) · BMC Medicine · doi:10.1186/s12916-017-0878-5 · Cited by 87
“In European people, HLA-B*5801 is a strong risk factor for AHS but is not sufficient or necessary to explain the disease, in contrast to Han Chinese and other Asian populations [63].”
BackgroundPavlos, R. K., Mallal, S. A., Ostrov, D. A., Pompeu, Y. A., & Phillips, E. J. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.11.005 · Cited by 87
Review of Toxic Epidermal Necrolysis
Harris, V., Jackson, C., & Cooper, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122135 · Cited by 86
“In addition to carbamazepine, allopurinol-induced SJS/TEN has been linked to the HLA-B 58:01 allele in both Asian and European populations [31,32].”
BackgroundYang, C., Wang, C., Zhang, S., Huang, J. H., & Zhou, P. (2014) · Molecular Simulation · doi:10.1080/08927022.2014.929127 · Cited by 85
“7 20235791 [20] Sulfamethoxazole SJS/TEN B*38:02 76 18192896 [21] Ticlopidine Hepatotoxicity A*33:03 13.”
Role of T cells in nonimmediate allergic drug reactions
Rozières, A., Vocanson, M., Saïd, B. B., Nosbaum, A., & Nicolas, J. (2009) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32832d565c · Cited by 85
An update on Stevens–Johnson syndrome and toxic epidermal necrolysis in children
Koh, M. J. A., & Tay, Y. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32832d1fef · Cited by 84
Ueta, M., Kannabiran, C., Wakamatsu, T. H., Kim, M. K., Yoon, K. C., Seo, K. Y., Joo, C.-K., Sangwan, V., Rathi, V. M., Basu, S., et al. (2014) · Scientific Reports · doi:10.1038/srep05981 · Cited by 84
Roujeau, J., Valeyrie‐Allanore, L., Liß, Y., & Mockenhaupt, M. (2009) · Dermatologica Sinica · doi:10.29784/ds.200912.0001 · Cited by 83
“But all four positive patients were from Asian ancestry, while none of 8 European patients had neither B*1502, nor any other associated allele.23 On the other hand, among allopurinolrelated SJS/TEN-cases we observed the same association with HLA-B*5801 as in patients from Taiwan.24 The association was weaker than in T…”
Self-citationSatapornpong, P., Jinda, P., Jantararoungtong, T., Koomdee, N., Chaichan, C., Pratoomwun, J., Nakorn, C. N., Aekplakorn, W., Wilantho, A., Ngamphiw, C., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00078 · Cited by 83
“The study reported the association of the alleles HLA-B*38:01 and HLAB*38:02 with sulfamethoxazole-induced SJS/TEN in European patients (Lonjou et al., 2008).”
BackgroundThe role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions
Illing, P. T., Purcell, A. W., & McCluskey, J. (2017) · Immunogenetics · doi:10.1007/s00251-017-1007-5 · Cited by 82
Ocular Features and Histopathologic Changes during Follow-up of Toxic Epidermal Necrolysis
López-García, J. S., Jara, L. R., García-Lozano, C. I., Conesa, E., de Juán, I. E., & del Castillo, J. M. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.06.035 · Cited by 82
Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
Yip, V. L. M., Alfirevic, A., & Pirmohamed, M. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8418-y · Cited by 83
Wang, C., Tassaneeyakul, W., Chen, C., Chen, W., Teng, Y.-C., Huang, C.-Y., Sukasem, C., Lu, C., Lee, Y.-S., Choon, S. E., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.003 · Cited by 81
Genetic Markers and Danger Signals in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Chung, W., & Chung, W. (2010) · Allergology International · doi:10.2332/allergolint.10-rai-0261 · Cited by 80
How to prevent allopurinol hypersensitivity reactions?
Stamp, L. K., & Barclay, M. L. (2017) · Rheumatology · doi:10.1093/rheumatology/kex422 · Cited by 80
Niihara, H., Kakamu, T., FUJITA, Y., Kaneko, S., & Morita, E. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2011.01457.x · Cited by 79
Li, H., Dai, Y., Huang, H., Li, L., Leng, S., Cheng, J., Niu, Y., Duan, H., Liu, Q., Zhang, X., et al. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.10325 · Cited by 78
Chen, Y., Cho, Y., Chang, C.-Y., & Chu, C. (2013) · Dermatologica Sinica · doi:10.1016/j.dsi.2013.09.006 · Cited by 77
Fakoya, A. O. J., Omenyi, P., Anthony, P. I., Anthony, F., Etti, P., Otohinoyi, D. A., & Olunu, E. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.148 · Cited by 77
“The study showed that HLA-B*1502 is not a confirmatory marker for any of the studied high-risk drugs known to cause SJS/TEN, and hence cannot be authoritatively labelled the cause of pathology in Europeans [10][11].”
BackgroundResultPharmacogenetics of Adverse Drug Reactions
Osanlou, O., Pirmohamed, M., & Daly, A. K. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.03.002 · Cited by 76
Genetic predisposition of life-threatening antiepileptic-induced skin reactions
Chung, W., Chung, W., & Chen, Y.-T. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903427969 · Cited by 76
“7 Association of HLA-B*1502 and carbamazepine Stevens-Johnson syndrome and toxic epidermal necrolysis in non-Asian countries A case series including 12 patients with CBZ–SJS/TEN from Europe, including Germany and France, showed no significant association between HLA-B*1502 and CBZ–SJS/TEN in caucasian patients [27,28].”
BackgroundKaniwa, N., Sugiyama, E., Saito, Y., Kurose, K., Maekawa, K., Hasegawa, R., Furuya, H., Ikeda, H., Takahashi, Y., Muramatsu, M., et al. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.180 · Cited by 75
Pharmacogenomics of off‐target adverse drug reactions
Garon, S. L., Pavlos, R. K., White, K. D., Brown, N. J., Stone, C. A., & Phillips, E. J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13294 · Cited by 75
Alfirevic, A., Gonzalez-Galarza, F., Bell, C., Martinsson, K., Platt, V., Bretland, G., Evely, J., Lichtenfels, M., Cederbrant, K., French, N., et al. (2012) · Genome Medicine · doi:10.1186/gm350 · Cited by 63
“Consistent with this, several genome-wide association studies conducted recently have identified a number of HLA alleles that are associated with a range of clinically diverse hypersensitivity reactions to structurally unrelated low-molecular weight compounds (Table 1) [4-22].”
ResultPark, D.-J., Kang, J., Lee, J., Lee, K., Wen, L., Kim, T., Park, Y., Park, S., & Lee, S. (2014) · Arthritis Care & Research · doi:10.1002/acr.22409 · Cited by 73
“As a result of these efforts, HLA-B5801 has been identified as a genetic risk factor for allopurinol-induced SCARs (3, 7, 11, 29-30).”
BackgroundPatch Testing for the Diagnosis of Anticonvulsant Hypersensitivity Syndrome: A Systematic Review
Elzagallaai, A. A., Knowles, S. R., Rieder, M. J., Bend, J. R., Shear, N. H., & Koren, G. (2009) · Drug Safety · doi:10.2165/00002018-200932050-00003 · Cited by 73
Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions
Zimmerman, D. E., & Dang, N. H. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_195 · Cited by 72
Genetic and ethnic risk factors associated with drug hypersensitivity
Kim, S., Ye, Y., Palikhe, N. S., Kim, J., & Park, H. (2010) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32833b1eb3 · Cited by 71
Tan, S., & Tay, Y. K. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1169 · Cited by 71
Karnes, J. H., Miller, M. A., White, K. D., Konvinse, K. C., Pavlos, R. K., Redwood, A., Peter, J., Lehloenya, R. J., Mallal, S. A., & Phillips, E. J. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021818 · Cited by 71
An, D., Wu, X., Hu, F., Yan, B., Stefan, H., & Zhou, D. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.10.006 · Cited by 70
Clinical perspectives in drug safety and adverse drug reactions
Pillans, P. I. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.5.695 · Cited by 69
HLA-B Alleles and Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Han Chinese Population
Shi, Y., Min, F., Liu, X., Zan, L.-X., Gao, M., Yu, M.-J., & Liao, W. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00681.x · Cited by 69
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study
Ciccacci, C., Fusco, D. D., Marazzi, M. C., Zimba, I., Erba, F., Novelli, G., Palombi, L., Borgiani, P., & Liotta, G. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1549-x · Cited by 69
Keller, S. F., Lu, N., Blumenthal, K. G., Rai, S. K., Yokose, C., Choi, J. W. J., Kim, S. C., Zhang, Y., & Choi, H. K. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212905 · Cited by 69
Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy
Wheatley, L. M., Plaut, M., Schwaninger, J. M., Banerji, A., Castells, M., Finkelman, F. D., Gleich, G. J., Guttman‐Yassky, E., Mallal, S. A., Naisbitt, D. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.027 · Cited by 68
Self-citationLu, N., Rai, S. K., Terkeltaub, R. A., Kim, S. C., Menendez, M. E., & Choi, H. K. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.03.014 · Cited by 67
Ueta, M., Sotozono, C., Nakano, M., Taniguchi, T., Yagi, T., Tokuda, Y., Fuwa, M., Inatomi, T., Yokoi, N., Tashiro, K., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.007 · Cited by 66
“Associations between HLA type and drug-induced severe cutaneous adverse reactions, including SJS and TEN, have been reported.(13-21) Patients with ocular involvement (50% to 68%)(8,11) exhibit severe conjunctivitis, and corneal epithelial defects often persist because of ocular surface inflammation.”
BackgroundUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes
Struck, M. F., Hilbert-Carius, P., Mockenhaupt, M., Reichelt, B., & Steen, M. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1659-1 · Cited by 65
Self-citationBousquet, P., Demoly, P. M., Romano, A. G., Aberer, W., Bircher, A. J., Blanca, M., Brockow, K., Pichler, W. J., Torres, M. J., Terreehorst, I., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2008.01944.x · Cited by 65
Self-citationYu, K., Yu, C., & Fang, Y. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13143 · Cited by 65
Genetic basis for idiosyncratic reactions to antiepileptic drugs
Franciotta, D. M., Kwan, P., & Perucca, E. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328328f276 · Cited by 65
Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
Chang, C., Chen, C., Chung, W., Ji, C., & Chung, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00969 · Cited by 64
Wang, C., Preclaro, I. A. C., Lin, W.-H., & Chung, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886377 · Cited by 64
“Although SCAR are rare, they affect approximately 2% of all hospitalized patients (ValeyrieAllanore et al., 2007), with an incidence between 2 and 7 cases of SJS/TEN cases/million/per year (Mockenhaupt et al., 2008; Levi et al., 2009; Sassolas et al., 2010; Sekula et al., 2013) and 1/ 1,000 to 1/10,000 cases of DRESS…”
BackgroundInfluentialGenetic Testing in Clinical Settings
Franceschini, N., Frick, A., & Kopp, J. B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.02.351 · Cited by 65
Deng, Y., Li, S., Zhang, L., Jin, H., & Zou, X. (2018) · Seizure · doi:10.1016/j.seizure.2018.06.024 · Cited by 64
Ueta, M., Sawai, H., Sotozono, C., Hitomi, Y., Kaniwa, N., Kim, M. K., Seo, K. Y., Yoon, K. C., Joo, C.-K., Kannabiran, C., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1916 · Cited by 63
Predicting allopurinol response in patients with gout
Wright, D. F. B., Duffull, S. B., Merriman, T. R., Dalbeth, N., Barclay, M. L., & Stamp, L. K. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12799 · Cited by 62
Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management
Hasegawa, A., & Abe, R. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003250 · Cited by 61
HLA and Delayed Drug-Induced Hypersensitivity
Sousa‐Pinto, B., Correia, C., Gomes, L. M. V. M. S., Gil‐Mata, S., Araújo, L. M., Correia, O., & Delgado, L. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000448217 · Cited by 61
“[87] found HLA-B * 58: 01 to be expressed in only 55% of patients with allopurinol-induced SJS/TEN, while a study by Gonçalo et al. [88] in Portuguese patients found the same allele to be present in 64% of patients with allopurinol-induced SJS/TEN and DRESS.”
BackgroundZhao, Q. S., Alhilali, K., Alzahrani, A., Almutairi, M., Amjad, J., Liu, H., Sun, Y., Sun, L., Zhang, H., Meng, X., et al. (2019) · Allergy · doi:10.1111/all.13769 · Cited by 61
Current perspectives on severe drug eruption
Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08859-0 · Cited by 60
“Burn center consultation and debridement may be required [84, 90, 91].”
BackgroundCristallo, A. F., Schroeder, J. W., Citterio, A., Santori, G., Ferrioli, G., Rossi, U. G., Bertani, G., Cassano, S., Gottardi, P., Ceschini, N., et al. (2011) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2011.01011.x · Cited by 59
“Our findings are consistent with a previous study (Lonjou et al., 2008) conducted in a group of European ancestry patients (RegiSCAR – European Registry of Severe Cutaneous Adverse Reactions to Drugs and Collection of Biological Samples) suffering from allopurinol-induced SJS ⁄ TEN in which was…”
BackgroundResultInfluentialToxic epidermal necrolysis: the year in review
Lee, H. Y., & Chung, W. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283630cc2 · Cited by 59
“Lamotrigine B 1502; B 38; B 5801, A 6801, Cw 0718, DQB1 0609, DRB1 1301 Han Chinese, Europeans, Europeans [17,23,29]”
Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)
Kuijper, E. C., French, L. E., Tensen, C. P., Vermeer, M. H., & Bavinck, J. N. B. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16339 · Cited by 59
the Utility of Genome-Wide Association Studies in Hepatology
Karlsen, T. H., Melum, E., & Franke, A. (2010) · Hepatology · doi:10.1002/hep.23564 · Cited by 58
“Strong HLA-B associations have also been reported in other immune-mediated drug reactions.(30) Despite an odds ratio of the HLA-B*5701 association of approximately 80, it is important to recognize that only between 1/500 and 1/1000 individuals with the HLA-B*5701 genotype will develop liver injury when treated with fl…”
Zeng, T., Long, Y., Min, F., Liao, W., & Shi, Y. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12570 · Cited by 58
Sukasem, C., Pratoomwun, J., Satapornpong, P., Klaewsongkram, J., Rerkpattanapipat, T., Rerknimitr, P., Lertpichitkul, P., Puangpetch, A., Nakkam, N., Konyoung, P., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1915 · Cited by 57
“The allele frequencies of HLA-A*11:02, HLA-B*15:02, and HLA-C*08:01 in CTX-induced SJS/TEN and tolerant controls are shown in Table 7 after pooling our results with those obtained by Kongpan et al. The frequency of HLA-B*15:02 and HLA-C*08:01 in CTX-SJS/TEN were significantly higher than the frequency found in toleran…”
BackgroundMethodInfluentialTsai, T., & Yeh, T.-Y. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11533190-000000000-00000 · Cited by 57
Paquet, P., & Pierard, G. (2010) · Drug Safety · doi:10.2165/11532540-000000000-00000 · Cited by 56
“Because these findings have not been confirmed in Caucasian patients, the genetic markers for SJS/TEN do not appear to be universal and ethnicity seems to be of prime importance.([166-169]) However, the high sensitivity/ specificity of some HLA markers provides a likely basis for developing tests identifying individua…”
BackgroundCheng, L. Z., Xiong, Y., Qin, C. Z., Zhang, W., Chen, X. P., Li, J., & Zhou, H. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13688 · Cited by 56
Frueh, F. W. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.62 · Cited by 55
Pharmacogenetics of Antiepileptic Drug-Induced Hypersensitivity
Bloch, K. M., Sills, G. J., Pirmohamed, M., & Alfirevic, A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.65 · Cited by 55
Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Cheng, L. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.588063 · Cited by 55
Severe Cutaneous Adverse Reactions
Mockenhaupt, M. (2009) · Springer eBooks · doi:10.1007/978-3-540-29316-3_34 · Cited by 55
Self-citationHarr, T., & French, L. E. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.04.004 · Cited by 54
Atzori, L., Pinna, A. L., Mantovani, L., Ferreli, C., Pau, M., Mulargia, M., & Aste, N. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04313.x · Cited by 54
Kasperavičiūtė, D., & Sisodiya, S. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.34 · Cited by 54
Chen, C., Chen, C., Chang, C., Lin, Y. J., Wang, C., Chi, C., Lu, C., Chen, W., Pan, R., Su, S., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1377 · Cited by 53
Clinical use of pharmacogenomic tests in 2009.
Sheffield, L. J., & Phillimore, H. (2009) · PubMed · Cited by 53
Elsheikh, A., Castrejón-Flores, J. L., Lavergne, S. N., Whitaker, P., Monshi, M. M., Callan, H., El-Ghaiesh, S. H., Farrell, J., Pichler, W. J., Peckham, D. G., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1119 · Cited by 53
A Recent Update of Pharmacogenomics in Drug-induced Severe Skin Reactions
Wei, C.-Y., Ko, T., Shen, C., & Chen, Y.-T. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-116 · Cited by 51
Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation
Su, S., Chung, W., Fan, W., Dao, R., & Chung, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111890 · Cited by 51
“Allopurinol SJS/TEN/DRESS B*58:01 Han Chinese Taiwan [30] Caucasian Europe [32] Thai Thailand [31] Japanese Japan [27]”
BackgroundResultInitiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
Lee, M. H., STOCKER, S. L., Anderson, J., Phillips, E. J., Nolan, D. A., Williams, K. M., Graham, G. G., Sullivan, J. R., & Day, R. O. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02567.x · Cited by 50
Niihara, H., Kaneko, S., Ito, T., Sugamori, T., Takahashi, N., Kohno, K., & Morita, E. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.04.013 · Cited by 50
“Although the relationship between HLA-B*58:01 and allopurinol-induced Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) has subsequently been studied in European and Japanese patients, the association was much weaker than that reported in Han Chinese patients [2,3].”
ResultKirchheiner, J., & Brockmöller, J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.274 · Cited by 50
Wang, D., Curtis, A., Papp, A. C., Koletar, S. L., & Para, M. F. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-32 · Cited by 49
“Recently, one study has demonstrated weak association between HLA B*38 and SMX induced Stevens-Johnson syndrome [22], while another study failed to find association between SMX hypersensitivity and HLA-DRB1 (MHC class II) [23].”
Boland, M. R., Jacunski, A., Lorberbaum, T., Romano, J. D., Moskovitch, R., & Tatonetti, N. P. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1323 · Cited by 48
“For example, the allele HLA-B*1502 is associated with carbamazepine-induced ADRs among both Thai(73) and Han Chinese(74) populations, whereas HLAA*3101 occurs in Japanese populations(75) and no HLA-B alleles are associated in European populations.(76) Stratification by ethnicity has been a crucial tool for understandi…”
BackgroundClinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
Knowles, S. R., & Shear, N. H. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01260.x · Cited by 49
“%) and in European Caucasians (0–0.1”
BackgroundInfluentialImmunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions
Wang, C., Dao, R., & Chung, W. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000286 · Cited by 49
“The association was also reported among the Japanese [21], Europeans [22], Thais [23], and Koreans [24].”
BackgroundKlaewsongkram, J., Sukasem, C., Thantiworasit, P., Suthumchai, N., Rerknimitr, P., Tuchinda, P., Chularojanamontri, L., Srinoulprasert, Y., Rerkpattanapipat, T., Chanprapaph, K., et al. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.05.004 · Cited by 48
Clinical Risk Factors for Adverse Events in Allopurinol Users
Ryu, H. J., Song, R., Kim, H. W., Kim, J., Lee, E. Y., Lee, Y. J., Wook, S. Y., & Lee, E. B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012439715 · Cited by 48
Rapid screening for the detection of HLA‐B57 and HLA‐B58 in prevention of drug hypersensitivity
Kostenko, L., Kjer‐Nielsen, L., Nicholson, I., Hudson, F., Lucas, A., Foley, B. A., Chen, K., Lynch, K., Nguyen, J., Wu, A. H. B., et al. (2011) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01649.x · Cited by 47
Recent advances in the understanding of severe cutaneous adverse reactions
Adler, N. R., Aung, A. K., Ergen, E. N., Trubiano, J. A., Goh, M., & Phillips, E. J. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15423 · Cited by 47
Wu, R., Cheng, Y., Zhu, L.-L., Yu, L., Zhao, X., Jia, M., Wen, C., Long, X.-Z., Tang, T. S., He, A.-J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13250 · Cited by 47
“Most studies were conducted among East Asian populations, 2 studies examined individuals of white race [16, 24], and 1 studies evaluated multi-ethnic populations [27].”
Background
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.